Fundraising Fox
Neotis
1 known investors
Find your way into Neotis
Sign up to see every warm intro you have to Neotis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neotis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Neotis develops immunotherapies to counteract age-related tissue decline by directing the immune system, with an initial focus on fibrotic disease. The company combines expertise in immunology, senescence, and biomarker development.
Founders & leadership
CM
Cathal Meehan, PhDCEOCathal Meehan holds a PhD in bioinformatics from the University of Warwick, with research focused on plant genomics and crop improvement, and has held roles in diagnostics development and biomarker discovery at Paris-based biotech firms before co-founding Neotis as CEO.
MS
Michael Saitakis, PhDCSO
Investors · 1
Related companies · 1
Companies working in the same space as Neotis.
Frequently asked questions
- What does Neotis do?
- Neotis develops immunotherapies to counteract age-related tissue decline by directing the immune system, with an initial focus on fibrotic disease. The company combines expertise in immunology, senescence, and biomarker development.
- Who are Neotis's investors?
- Neotis's investors include Daphni.